scholarly journals Surgical management of giant cell tumor in adolescent by excision or curettage followed by fibular strut graft

2021 ◽  
Vol 8 (1) ◽  
pp. 76
Author(s):  
K. Vijaya Bhaskar Reddy ◽  
N. Brahma Chary ◽  
Chenna K. Mogili
Keyword(s):  
Giant Cell ◽  
Surgical Management ◽  
Proximal Tibia ◽  
Giant Cells ◽  
Fibular Graft ◽  
Rare Tumour ◽  
Strut Graft ◽  
Fibular Strut ◽  
Good Range

<p class="abstract">Giant cell tumour (GCT) in adolescent is a rare tumour. It commonly occurs in skeletally mature patients aged between 20-40 years. In adults it is seen in epiphyseal region. In patients with intact physis, it arises from the metaphysis. Giant cells are more common in females. It is more common in the ends of long bones of distal end of femur, proximal tibia, and distal radius. 14 cases of surgical management of GCT by excision or curettage in adolescent followed by fibular strut graft. 1 year follow up of all cases of GCT in adolescent treated with excision or curettage followed by fibular strut graft was done. Out of 14 patients, 12 patients did not develop any recurrence of GCT. 2 patient developed recurrence after 6 months. All the patients were able to attain good range of movements 2 months after surgery. GCT in adolescent surgically treated with excision or curettage followed by fibular graft had excellent results in terms of recovery of daily activities, wound healing. Chances of recurrence more in patients treated with curettage and bone grafting.</p><p class="abstract"> </p>

scholarly journals Giant Cell Urothelial Carcinoma of Bladder

2021 ◽  
Vol 2021 ◽  
pp. 1-5
Author(s):  
Harshima Disvini Wijesinghe ◽  
Ajith Malalasekera
Keyword(s):  
Urothelial Carcinoma ◽  
Giant Cell ◽  
Early Stage ◽  
Giant Cells ◽  
World Health ◽  
World Health Organization Classification ◽  
Health Organization

Giant cell urothelial carcinoma is a rare variant of bladder cancer recognized by the current World Health Organization classification of urologic tumours. It is an aggressive tumour with a poor prognosis that usually presents at an advanced stage. It is characterized histologically by pleomorphic giant cells. We discuss a case of giant cell urothelial carcinoma presenting at an early stage in a previously well 62-year-old woman. Histology showed a tumour comprising pancytokeratin positive bizarre mononuclear and multi-nuclear giant cells admixed with areas of conventional urothelial carcinoma and carcinoma in situ. Three-month follow-up cystoscopy and magnetic resonance imaging showed no evidence of recurrence or pelvic lymphadenopathy.

Giant Cell Lesions with a Noonan-like Phenotype: A Case Report

2007 ◽  
Vol 8 (4) ◽  
pp. 67-73 ◽  
Author(s):  
Manoel Sant'Ana Filho ◽  
Claudia Marcela H. Cancino ◽  
Léonilson Gaião ◽  
Flavio Augusto Marsiaj Oliveira
Keyword(s):  
Case Report ◽  
Giant Cell ◽  
Surgical Intervention ◽  
Heart Defects ◽  
Sporadic Case ◽  
Giant Cells ◽  
The Body ◽  
Phenotypic Characteristics ◽  
Previous Diagnosis

Abstract Aim The purpose of this article is to describe a case of multiple giant cell lesions of the mandible that occurred in a 14-year-old girl with phenotypic characteristics associated with Noonan Syndrome (NS). Background NS is a dysmorphic disorder characterized by hypertelorism, short stature, congenital heart defects, short and webbed neck, skeletal anomalies, and bleeding diathesis. Report A 14-year-old girl with a previous diagnosis of NS (sporadic case) presented with multiple radiolucent lesions in the body and ramus of her mandible. Summary In terms of clinical behavior and the described radiographic characteristics, giant cells lesions with Noonan-like phenotype can be considered a form of cherubism. Therefore, surgical intervention is not necessary, but radiographic follow-up and observation is very important during the control and gradual regression of the lesions. Citation Cancino CMH, Gaião L, Sant'Ana Filho M, Oliveira FAM. Giant Cell Lesions with a Noonan-like Phenotype: A Case Report. J Contemp Dent Pract 2007 May;(8)4:067-073.

scholarly journals Use of Nonvascularized Autologous Fibular Strut Graft in the Treatment of Major Bone Defect after Periprosthetic Knee Fracture

2017 ◽  
Vol 2017 ◽  
pp. 1-5
Author(s):  
Vincenzo Giordano ◽  
Bruno Parilha Coutinho ◽  
Mateus Kenji Miyahira ◽  
Felipe Serrão Mendes de Souza ◽  
Ney Pecegueiro do Amaral
Keyword(s):  
Femur Fracture ◽  
Strut Graft ◽  
Level Of Activity ◽  
Donor Graft ◽  
Total Knee ◽  
A Minor ◽  
Open Fracture Reduction ◽  
Fibular Strut

We present the case of a patient who suffered a comminuted supracondylar periprosthetic femur fracture. The patient was an 86-year-old lady who suffered a minor fall at home and presented at our hospital with a right comminuted distal femur fracture around a total knee arthroplasty. The patient was submitted to a cruciate-sacrificing total knee replacement 6 years before at the same institution. Despite severe metaphyseal fragmentation and short distal fragment, the prosthesis was stable; thus, open fracture reduction and stabilization with internal fixation were performed. The surgical technique included the use of a nonvascularized autologous fibular strut graft as an augmentation technique in conjunction with double plating fixation. Clinically, patient presented a painless aligned knee 12 months after femur fixation, although she was not able to return to an independent level of activity. No pain involving the donor graft site was reported at the time of the most recent follow-up examination. This case study demonstrates the use of free nonvascularized autogenous fibular strut bone graft as an option to bridge major bone defects. This proved to be a relatively simple, not expensive procedure that can be done percutaneously and does not need high-quality training.

scholarly journals Peripheral giant cell granuloma associated with a dental implant

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Rafaela Carriço Porto Baesso ◽  
Maria Carolina de Lima Jacy Monteiro Barki ◽  
Rebeca de Souza Azevedo ◽  
Karla Bianca Fernandes da Costa Fontes ◽  
Débora Lima Pereira ◽  
...  
Keyword(s):  
Giant Cell ◽  
Histological Examination ◽  
Dental Implant ◽  
Excisional Biopsy ◽  
Giant Cells ◽  
Giant Cell Granuloma ◽  
Case Presentation ◽  
Peripheral Giant Cell Granuloma ◽  
Left Mandible

Abstract Background Peripheral giant cell granuloma (PGCG) is an uncommon pathology that affects gingival or alveolar mucosa. Although PGCG can be associated with dental implants, little is known about this lesion and implant osseointegration as well as its etiopathogenesis and the treatments available. This study sought to report a rare case of PGCG associated with dental implant, emphasizing its clinical and histopathological aspects. Case presentation A 53-year-old man had an exophytic, reddish lesion, around a crown attached to a dental implant located in the left mandible. Radiographically, there was bone loss around the implant. After excisional biopsy, histological examination revealed a submucosal proliferation of multinucleated giant cells rendering the diagnosis of peripheral giant cell granuloma. Patient has been under follow-up for 6 months with no recurrence. Conclusions Peri-implant lesions must be completely removed to prevent recurrence of PGCG and implant failure, even in cases suspected to be reactive. Besides, histological examination must be performed on all peri-implant reactions to achieve the appropriate diagnosis and, consequently, the best treatment and follow up.

scholarly journals Recurrent novel HMGA2-NCOR2 fusions characterize a subset of keratin-positive giant cell-rich soft tissue tumors

2021 ◽  
Author(s):  
Abbas Agaimy ◽  
Michael Michal ◽  
Robert Stoehr ◽  
Fulvia Ferrazzi ◽  
Pavel Fabian ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Giant Cell ◽  
Mononuclear Cells ◽  
Giant Cells ◽  
Soft Tissue Tumors ◽  
Low Grade ◽  
Giant Cell Tumors ◽  
Type Giant ◽  
Metaplastic Bone

AbstractGiant cell tumors of soft tissue (GCT-ST) are rare low-grade neoplasms that were at one time thought to represent the soft tissue counterparts of GCT of bone (GCT-B) but are now known to lack the H3F3 mutations characteristic of osseous GCT. We present six distinctive giant cell-rich soft tissue neoplasms that expressed keratins and carried a recurrent HMGA2-NCOR2 gene fusion. Patients were five females and one male aged 14–60 years (median, 29). All presented with superficial (subcutaneous) masses that were removed by conservative marginal (3) or wide (2) local excision. The tumors originated in the upper extremity (2), lower extremity (2), head/neck (1), and trunk (1). Five patients with follow-up (median, 21 months; range, 14–168) remained disease-free. Grossly, all tumors were well-demarcated but not encapsulated with variable lobulation. Histologically, they were composed of bland plump epithelioid or ovoid to spindled mononuclear cells admixed with evenly distributed multinucleated osteoclast-type giant cells. Foci of stromal hemorrhage and hemosiderin were seen in all cases. The mitotic activity ranged from 2 to 14/10 high power fields (median: 10). Foci of necrosis and vascular invasion were seen in one case each. The mononuclear cells were immunoreactive with the AE1/AE3 keratin cocktail and less frequently/less diffusely for K7 and K19 but lacked expression of other lineage-associated markers. RNA-based next-generation sequencing revealed an HMGA2-NCOR2 fusion in all tumors. None of the keratin-negative conventional GCT-ST showed the HMGA2-NCOR2 fusion (0/7). Metaplastic bone (4/9) and SATB2 expression (3/4) were frequent in keratin-negative conventional GCT-ST but were lacking in keratin-positive HMGA2-NCOR2 fusion-positive tumors. The distinctive immunophenotype and genotype of these tumors strongly suggest that they represent a discrete entity, differing from conventional GCT-ST and other osteoclast-rich morphologic mimics. Their natural history appears favorable, although a study of additional cases and longer follow-up are warranted.

FIBULAR STRUT GRAFTING FOR GIANT CELL TUMORS OF THE PROXIMAL TIBIA

Orthopedics ◽  
1978 ◽  
Vol 1 (5) ◽  
pp. 389-393
Author(s):  
D Elliott O'Reilly ◽  
Anver A Tayob ◽  
James Kelly
Keyword(s):  
Giant Cell ◽  
Proximal Tibia ◽  
Giant Cell Tumors ◽  
Fibular Strut

scholarly journals Giant cell tumor distal end radius: resection and reconstruction using proximal fibular graft

2021 ◽  
Vol 7 (2) ◽  
pp. 409
Author(s):  
Rahul Bharadwaj ◽  
Vipin Sharma ◽  
Narinder Singh ◽  
Narinder Singh
Keyword(s):  
Range Of Motion ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Giant Cell Tumour ◽  
Wrist Joint ◽  
Cell Tumor ◽  
Fibular Graft ◽  
Primary Tumors ◽  
One Year

<p>Giant cell tumour forms 4% of all primary tumors. GCT distal radius is very rare. Current study presents a case of a 27 year female who was managed by wide excision and reconstruction with ipsilateral fibula. At one year follow up, patient had excellent range of motion at wrist joint and hand.</p>

scholarly journals Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: a case series analysis and literature review

ESMO Open ◽  
2020 ◽  
Vol 5 (4) ◽  
pp. e000663 ◽  
Author(s):  
Alessandra Raimondi ◽  
Noemi Simeone ◽  
Marco Guzzo ◽  
Massimo Maniezzo ◽  
Paola Collini ◽  
...  
Keyword(s):  
Giant Cell ◽  
Clinical Features ◽  
Giant Cell Tumour ◽  
Locally Advanced ◽  
Case Series ◽  
Osteonecrosis Of The Jaw ◽  
Cell Tumour ◽  
Ozone Therapy ◽  
Rare Tumour

ObjectivesGiant cell tumour of bone (GCTB) is a rare tumour, generally managed with surgery. Treatment of the very rare unresectable advanced/metastatic GCTB is challenging and denosumab is the only current available medical option, an anti-RANKL monoclonal antibody inhibiting osteolysis. An uncommon but severe and treatment-limiting adverse event of denosumab is the osteonecrosis of the jaw (ONJ). The clinical management of GCTB patients stopping denosumab for medication-related (MR)-ONJ and the possible reintroduction of denosumab after MR-ONJ resolution is matter of debate. We performed a retrospective study to describe the incidence, clinical features and outcome of MR-ONJ in unresectable GCTB patients treated with denosumab at our Institution.Design and settingRetrospective, single-institutional study.ParticipantsAdult patients receiving denosumab as antineoplastic therapy for GCTB and experiencing MR-ONJ at Fondazione IRCCS Istituto Nazionale Tumori of Milan between January 2008 and July 2019.Main outcome measuresIncidence, time of onset and clinical features of MR-ONJ.Results29 patients with locally advanced and/or metastatic GCTB treated with denosumab were identified. At a median follow-up of 70 months (range 1–125), 4 (13.8%) patients experienced MR-ONJ while on treatment, after 125, 119, 85 and 41 months of denosumab, respectively. All patients showed an ongoing tumour stabilisation with denosumab at the MR-ONJ onset and in all cases denosumab was stopped. All four patients were treated with ozone therapy. Two are waiting for surgery, two were already operated on. Both of them experienced disease progression and were thus rechallenged with denosumab. One is still on therapy after 25 months. The other had an MR-ONJ relapse after 39 months and was treated again with ozone therapy and surgery. She is under surveillance, GCTB being currently stable.ConclusionA clinical algorithm of denosumab rechallenge after complete resolution of MR-ONJ in progressing GCTB patients should be prospectively validated.

scholarly journals Peripheral Giant Cell Granuloma Associated with a Dental Implant: A Case Report and Review of the Literature

2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Amy Louise Brown ◽  
Paulo Camargo de Moraes ◽  
Marcelo Sperandio ◽  
Andresa Borges Soares ◽  
Vera Cavalcanti Araújo ◽  
...  
Keyword(s):  
Giant Cell ◽  
Dental Implant ◽  
Excisional Biopsy ◽  
Giant Cells ◽  
Infectious Agents ◽  
Giant Cell Granuloma ◽  
Review Of The Literature ◽  
Peripheral Giant Cell Granuloma ◽  
Foreign Body Reactions

The peripheral giant cell granuloma (PGCG) is a nonneoplastic lesion commonly caused by local irritation. This report describes a 46-year-old Caucasian male who presented with a PGCG associated with a dental implant. The dental implant was originally placed in August 2012. Ten months later, the patient presented with a well-circumscribed lesion associated with and covering the implant, at which time the lesion was excised. Four months later, due to recurrence of the lesion, a deeper and wider excisional biopsy with curettage of the adjacent bone was performed. No evidence of recurrence has been reported after 12 months of follow-up. Immunohistochemistry, using the antibody CD68, was performed to investigate the origin of the multinucleated giant cells, with their immunophenotype being similar to those of other giant cell lesions, including central giant cell granuloma, foreign-body reactions, and granulomatous reactions to infectious agents.

scholarly journals Peripheral giant cell granuloma: a case repo

2016 ◽  
Vol 4 (2) ◽  
pp. 44
Author(s):  
Saad Shahnawaz Ahmed ◽  
Hira Zaman ◽  
Fahad Bin Abrar ◽  
Sadia Khalid
Keyword(s):  
Giant Cell ◽  
Stromal Cells ◽  
Unknown Origin ◽  
Giant Cells ◽  
Giant Cell Granuloma ◽  
Cell Hyperplasia ◽  
Peripheral Giant Cell Granuloma ◽  
Good Healing ◽  
Chronic Trauma

Peripheral giant cell granuloma (PGCG) is a common benign gingival lesion in the oral cavity of unknown origin, believed to be stimulated by local irritation or chronic trauma. It is also known as giant cell epulis, giant cell reparative granuloma, or giant-cell hyperplasia, presenting as purplish-red soft tissue nodule clinically and histologically consisting of multinucleated giant cells in a background of mononuclear stromal cells and extravasated red blood cells. This case report describes a 40 year old male previously reported with peripheral giant cell granuloma 2 years back which on excision reoccurred after 3-4 months and persistently growing since then. The gingival lesion between his maxillary central incisors was excised and the Biopsy specimen sent in 10% formalin to histopathological lab and was diagnosed as PGCG. There was good healing of tissue of the surgical site during the 9 months follow-up.

Sign in / Sign up

Export Citation Format

Share Document